恒瑞医药董事长 孙飘扬 作为国内创新药龙头企业，恒瑞医药面对医药行业技术创新与同质化竞争并存的复杂局面，2025年在创新研发与国际拓展方面取得关键 突破，全年获批7款1类创新药，创新药上市总数达24款，并成功实现"A+H"双资本平台布局。2026年，恒瑞医药董事长孙飘扬表 示："要持续加大研发投入，聚焦肿瘤、自免、代谢疾病等重点领域，进一步构筑'新、特、快'产品核心优势，深化ADC、双抗等技术平 台建设，催生更多差异化创新成果，解决未获满足的临床需求。"同时通过强化全球临床布局与商业化能力，系统推动中国创新药在国 际市场的价值实现，以可持续的创新生态助力健康中国建设。 背景介绍： 当2025年的日历翻至末页，生物医药产业正站在一个特殊的历史节点——这既是"十四五"的收官沉淀之年，更是"十五五"宏伟蓝图的启 航之时。这一年，技术狂飙与商业理性的碰撞、全球化布局与本土化深耕的平衡、"创新驱动"向"价值驱动"的范式转型，共同勾勒出 2025年的行业主线。2026年，产业如何跨越技术周期与资本周期的双重考验，在"健康中国"战略与全球创新格局双轨并行中，探寻可持 续增长路径？思享启发思想，"生物医药大健康2026思享汇 ...

Core Viewpoint - Shanghai Yizhong (688091.SH) expects significant growth in both revenue and net profit for the fiscal year 2025, driven by the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance directory [1] Financial Performance - The company anticipates a revenue of 317 million yuan for 2025, representing an increase of 82.72% compared to the previous year [1] - Net profit attributable to the parent company is projected to be 64.132 million yuan, reflecting a growth of 819.42% year-on-year [1] - The net profit after deducting non-recurring gains and losses is expected to reach 60.1208 million yuan, marking a staggering increase of 1,444.75% [1] Product Development - The core product, paclitaxel micelles, has been officially included in the national medical insurance directory in 2025, significantly enhancing market access and patient numbers, which has driven revenue and profit growth [1] - The company is intensifying its R&D efforts, focusing on innovative drugs YXC-001 (a multifunctional monoclonal antibody targeting PD-1, VEGF, and IL-2) and YXC-002 (a fourth-generation small molecule targeted drug), achieving significant breakthroughs in their development [1] - Ongoing Phase III clinical trials for paclitaxel micelles in pancreatic cancer and breast cancer are being conducted steadily [1] R&D Investment - The R&D expenditure for the year is expected to be approximately 85.0603 million yuan, an increase of about 128.63% compared to the previous year [1] - The company is enhancing the management of sales and administrative expenses to ensure reasonable spending and effective control, allowing for substantial profit growth while maintaining R&D investment [1]

Group 1 - The company Changchun Gaoxin (000661) expects a significant decline in net profit for the fiscal year 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% [1] - The net profit after deducting non-recurring gains and losses is anticipated to be between 437 million and 507 million yuan, reflecting a year-on-year decline of 82.09% to 84.56% [1] - Basic earnings per share are expected to be between 0.37 yuan and 0.55 yuan, a substantial drop from 6.42 yuan per share in the same period last year [1] Group 2 - The decline in net profit is attributed to increased R&D expenses as the company focuses on traditional strengths in endocrine metabolism and women's health, as well as innovative directions related to tumors, respiratory, and immune systems [1] - The company has launched its first domestic treatment for acute gouty arthritis, the innovative biological agent Jinbeixin (Fuxin Qibai monoclonal antibody), along with several other new products, leading to increased sales expenses [1] - The company's subsidiary, Changchun Baike Biotechnology Co., Ltd., is expected to report losses for the fiscal year 2025, which will further impact the company's overall performance [1] Group 3 - Changchun Jinsai Pharmaceutical Co., Ltd., a subsidiary of the company, has authorized its wholly-owned subsidiary Shanghai Saizeng Medical Technology Co., Ltd. to enter into an exclusive licensing agreement with Yarrow Bioscience, Inc. for the GenSci098 injection project [2] - The licensing agreement's related payments will not be recognized in the current reporting period due to accounting policy requirements and actual payment timelines, thus not affecting the current period's performance [2]

1月31日，君实生物发布业绩预告，预计去年全年实现营业收入约25亿元，同比增长约28.32%；预计归母净利润亏损约8.73亿元，同比减亏31.85%；作为 创新药公司，公司自2020年7月上市以来至今已5年半，仍未扭转亏损态势，5年累计亏损约92亿元。 对于业绩变化，君实生物解释称，报告期内，主要系商业化药品的销售收入与上年同期相比有所增长。报告期内，公司核心产品特瑞普利单抗注射液(商 品名：拓益)于国内市场销售收入同比大幅增长。截至公告披露日，拓益已在中国内地获批上市的12项适应症全部纳入国家医保目录，是目录中唯一用于 肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物。 公司表示，去年归母净利润仍出现亏损，但亏损金额相比显著缩窄，主要系公司商业化能力显著提升的同时不断加强费用管控与资源聚焦。 截至目前，特瑞普利单抗已在中国内地、中国香港、美国、欧盟、印度、英国、约旦、澳大利亚、新加坡、阿联酋、科威特、巴基斯坦、加拿大和巴林等 40多个国家和地区获批上市，并在全球多个国家和地区接受上市审评。 值得一提的是，最近几个月君实生物率遭股东减持。去年12月18日晚间，君实生物称，上海檀英计划通过大宗交易的方式减持 ...

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on TCM and high-end generic drugs. The revenue from TCM has historically contributed over 50% of total revenue, while the share of chemical drugs has increased from 24% in 2016 to 36% in 2024 [13][16]. - The company launched an employee stock ownership plan in 2024 to incentivize core personnel, focusing on performance assessment and innovative drug development [23][24]. 2. Innovative Product Data and Growth Potential - The company has several innovative products entering commercialization or late-stage clinical trials. Notably, RAY1225, a dual-target drug for obesity and diabetes, has shown superior efficacy in clinical trials compared to existing treatments [27][29]. - ZSP1601, a first-in-class drug for NASH, is currently in IIb phase clinical trials and has demonstrated promising results in reducing liver inflammation markers [45][49]. 3. Core TCM Products and Market Recovery - The company's core TCM product, Compound Thrombus Tong Capsule, has maintained a leading market share in the ophthalmic TCM sector. As the impact of centralized procurement diminishes, sales are expected to stabilize and recover [9][18]. - The Brain Thrombus Capsule, another key product, has shown stable clinical demand and is projected to continue its steady growth [9][18].

Investment Rating - The report does not explicitly state an investment rating for the surgical robot industry, but it indicates a positive outlook for growth and development in the sector. Core Insights - The surgical robot industry in China is entering a rapid development phase, supported by national policies and capital investment, with significant advancements in technology and market demand [13]. - The report highlights the transition from a capital-driven to a value-driven model in the surgical robot sector, emphasizing the importance of clinical applications and technological integration [13]. - The approval process for surgical robots by the NMPA has accelerated, particularly for orthopedic surgical robots, which dominate the market in terms of the number of products approved [30][28]. Summary by Sections Market Overview - The surgical robot market in China is characterized by a growth in sales volume, with a total of 332 units sold in the first 11 months of 2025, reflecting a year-on-year increase of 3.75% [34]. - The sales revenue for surgical robots reached 2.973 billion yuan, showing a slight decline of 0.87% year-on-year, indicating a structural transition rather than a market downturn [34]. Technological Advancements - Innovations in remote operation, miniaturization, and AI assistance are driving the development of surgical robots, with products like the TUMAI® remote surgical robot achieving significant milestones in cross-border surgeries [16][19]. - The introduction of AI-assisted surgical robots is enhancing precision in surgeries, with products capable of 3D reconstruction and personalized surgical planning [16]. Regulatory Developments - The National Healthcare Security Administration has established a pricing framework for surgical robots, which is expected to facilitate market growth by clarifying reimbursement policies and pricing structures [27][26]. - The pricing guidelines categorize surgical robot services into navigation, participation in execution, and precision execution, linking them to main surgical procedures [27]. Market Segmentation - The orthopedic surgical robot segment holds the largest market share, accounting for 50% of the total NMPA-approved surgical robots from 2014 to 2024, followed by neurosurgical robots [30]. - The report indicates a significant potential for growth in emerging fields such as vascular surgery robots, with increasing demand and technological advancements [34]. Competitive Landscape - The report identifies key players in the surgical robot market, including domestic manufacturers that are rapidly gaining market share as regulatory barriers for imports increase [45]. - The competitive landscape is shifting as domestic products receive NMPA approval, challenging the previously dominant imported products [45].

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on eye care, cardiovascular, respiratory, and digestive diseases. Revenue for the first three quarters of 2025 was 1.89 billion CNY, a decrease of 1.0% year-on-year, while net profit attributable to the parent company was 250 million CNY, an increase of 68.4% [13][9]. - The core TCM product, Compound Thrombus-Relieving Capsule, is a unique original formulation with a leading market share in the domestic ophthalmic TCM sector. The impact of centralized procurement is gradually being digested, and sales are expected to stabilize [9][10]. 2. Innovative Product Data and Growth Potential - The company has multiple innovative products entering commercialization or late-stage clinical trials. The PB2-targeted RNA polymerase inhibitor, Anladiwei Tablets, was approved in May 2025 for treating adult uncomplicated influenza, showing competitive advantages over Oseltamivir [9][27]. - The GLP-1/GIP dual-target drug RAY1225 for obesity and diabetes has entered Phase III clinical trials, with promising results indicating better weight loss efficacy compared to existing treatments [27][29]. 3. Financial Forecast and Investment Recommendations - The company’s revenue is projected to recover, with expected revenues of 2.803 billion, 3.126 billion, and 3.447 billion CNY for 2025, 2026, and 2027 respectively, reflecting growth rates of 13.6%, 11.5%, and 10.3% [5]. - The report emphasizes the importance of innovation and performance assessment, with an employee stock ownership plan launched in 2024 to incentivize core personnel [23][24].

Core Insights - A lesser-known Chinese company has developed a new drug that outperforms the world's best-selling cancer medication, highlighting the progress of China's innovative pharmaceutical sector [1] - The Chinese government has been actively promoting the development of innovative drugs, emphasizing the importance of self-reliance in the biopharmaceutical industry [1] Group 1: Industry Development - From 2015 to 2025, China's innovative drug sector has seen a significant increase in research and development investment, streamlined approval processes, and expanded market opportunities, forming a "golden triangle" of technology, policy, and capital [2] - The number of clinical trial applications for innovative drugs in China has increased twelvefold, with notable approvals for domestic PD-1 monoclonal antibodies, HPV vaccines, and PARP inhibitors [2] Group 2: Market Achievements - By 2025, China has approved 76 innovative drugs, surpassing the previous year's total of 48, marking a historical high [5] - The total value of innovative drug licensing transactions in China has exceeded $130 billion, with over 150 transactions, both figures representing record highs [5] Group 3: Accessibility and Affordability - A newly developed diabetes treatment has been included in the national medical insurance directory, costing patients only 10 yuan per day, reflecting the government's commitment to making innovative drugs accessible [6] - The time taken for new drugs to be included in the medical insurance directory has been reduced from approximately five years to about one year, with around 80% of innovative drugs being added within two years of market approval [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计，公司已就业绩预告有关事项与会计师事务所进行预先沟通，公司 与会计师事务所在业绩预告方面不存在重大分歧。 三、业绩变动原因说明 1、公司受国家药品、医疗器械招标、集采政策持续推进的影响，集采覆盖区域的进一步扩大，公司相 关产品集采后价格下降明显，行业市场竞争加剧，在第十批国家集采中有产品未能中标，造成公司利润 大幅度下降。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为负值 单位：万元 ■ 本次业绩预告是公司财务部门初步测算的结果，具体财务数据以公司披露的《2025年年度报告》为准。 敬请广大投资者谨慎决策，注意投资风险。 特此公告。 万邦德医药控股集团股份有限公司 董事会 2026年1月31日 2、公司由仿制药向创新药战略发展转型升级，加速创新药全球研发力度，研发投入加大。 3、公司创新药国际化制剂车间、原料药基地、中非医疗科技园国际 ...

一、本期业绩预告情况 证券代码：688180 证券简称：君实生物 公告编号：临2026-003 上海君实生物医药科技股份有限公司2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年年度实现营业收入250,000.00万元左右，与上年同期相比增长 55,168.27万元左右，同比增长28.32%左右。 2、预计2025年年度研发费用为135,300.00万元左右，与上年同期相比增长7,772.99万元左右，同比增长 6.10%左右。 3、预计2025年年度实现归属于母公司所有者的净利润-87,300.00万元左右，与上年同期相比亏损减少 40,792.64万元左右，同比亏损减少31.85%左右。预计2025年年度扣除股份支付影响后实现归属于母公 司所有者的净利润-79,900.00万元左右，与上年同期相比亏损减少48,192.64万元左右，同比亏损减少 37.62%左右。 4、预计2 ...